Kymera Therapeutics Stock Jumps After Positive Data From Atopic Dermatitis Trial

• Kymera Therapeutics Inc (NASDAQ: KYMR) announced clinical results from the patient cohort portion of its KT-474 (IRAK4) Phase 1 trial in hidradenitis suppurativa (HS) and atopic dermatitis (AD) patients.

• KT-474 demonstrated robust IRAK4 knockdown in blood and active skin lesions and systemic suppression of proinflammatory cytokines and chemokines with a favorable safety profile.

• KT-474 showed IRAK4 knockdown in blood and skin comparable to MAD3, with maximum degradation exceeding 90%. Target degradation was similar across HS and AD patients in blood and skin.

• In ex vivo cytokine stimulation assays, KT-474 demonstrated broad and deep inhibition of multiple disease-relevant cytokines, including inhibition of up to 84% in HS and up to 98% in AD.

• KT-474 also reduced several circulating cytokines and acute phase reactants in vivo.

• Sanofi (NASDAQ: SNY), collaborating with Kymera on developing KT-474 (SAR444656) outside of the oncology and immune-oncology fields, has notified Kymera of its commitment to advance KT-474 into Phase 2 clinical studies.

• The initial Phase 2 trial of KT-474 will investigate its potential in HS and AD, with the first study initiating in 2023.

• Price Action: KYMR shares are up 22.2% at $31.57 on the last check Wednesday.

• Photo Via Company

See more from Benzinga

• Harrow Health Acquires Rights To Novartis' Five Approved Ophthalmic Products

• AbbVie, Ipsen Terminate Partnerships With Exicure As Bankruptcy Concern Looms

• Here's How Much A $1,000 Investment In Tesla Stock Will Be Worth In 2030 If Ron Baron's Price Target Hits

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.